drugset / Trial / NCT00981721

A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies

NCT00981721

Phase 1 Completed 20 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is being carried out to see how single and multiple doses of cediranib are handled by the body (that is how they are absorbed, broken down and got rid of from the body) by measuring levels of drug in the blood in Chinese patients with advanced solid malignancies. The study will also assess the tolerability of 20 or 30 mg cediranib in Chinese patients and how the tumour responds to treatment with cediranib.

Timeline

Start
2009-09
Primary completion
2010-05
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Cediranib Small molecule 20 mg Oral
Subject Cediranib Small molecule 30 mg Oral